Generic Products March 2020

Pharmacy Times, March 2020, Volume 88, Issue 3

This month's generic products feature products indicated for the treatment of gastroesophageal reflux disease, non-small cell lung cancer, and more.

ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES

MARKETED BY: Camber Pharmaceuticals, Inc

COMPARE TO: Nexium

Camber has launched esomeprazole magnesium delayed-release capsules for the treatment of a damaged esophagus, gastroesophageal reflux disease, heartburn, and stomach ulcers. The capsules are available in 20-mg and 40-mg doses, and in 30-, 90-, and 1000-count bottles. Acid reflux can be aggravated by activities, such as drinking alcohol or coffee, eating fatty or fried foods, and overeating, and taking some medications such as aspirin. Adverse effects of esomeprazole can include diarrhea, headaches, and nausea.

FOR MORE INFORMATION: camberpharma.com

DRONABINOL

MARKETED BY: Camber Pharmaceuticals, Inc

COMPARE TO: Marinol

Camber Pharmaceuticals has added Dronabinol capsules to its growing portfolio, indicated for the treatment of nausea and vomiting caused by chemotherapy in patients with cancer. Dronabinol is also used to treat loss of appetite and weight loss in patients with HIV. The drug is available in 2.5-mg, 5-mg, and 10-mg strengths in bottles of 60 capsules. Dronabinol is a man-made form of cannabis and therefore may cause new or worsening unusual behavior or thoughts. Common adverse effects

may include dizziness, drowsiness, and thinking problems.

FOR MORE INFORMATION: camberpharma.com

ERLOTINIB HYDROCHLORIDE

MARKETED BY: Breckenridge Pharmaceutical, Inc

COMPARE TO: Tarceva

Erlotinib hydrochloride tablets in 25-mg, 100-mg, and 150-mg strengths are indicated for the treatment of non—small cell lung cancer and pancreatic cancer. The tablets,

developed in collaboration with MEDIKL, will be manufactured and supplied by Natco Pharma Limited, and Breckenridge officials said that they plan to launch the product immediately. According to a company statement, Tarceva had a market value of about $145 million during the fiscal year that ended September 30, 2019.

Common adverse effects include diarrhea, fatigue, poor appetite, and rash.

FOR MORE INFORMATION: bpirx.com

FOSAPREPITANT

MARKETED BY: Fresenius Kabi

COMPARE TO: Emend

Fosaprepitant for injection is a substance P/neurokinin-1 receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy in adults, including high-dose cisplatin. It is also indicated for delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. The product comes in a dose strength of 150 mg per vial and offers clinicians a treatment alternative with a 24-month shelf life.

FOR MORE INFORMATION: fresenius-kabi.com